C2N Diagnostics has received a $15 million investment from GHR Foundation to develop non-invasive tests for tau tangles, crucial in Alzheimer's disease diagnosis.
Dr. Joel Braunstein emphasized that this new funding will enable C2N to add tau-based blood biomarkers to its portfolio, enhancing diagnostic precision and aiding patient care.
The collaboration with GHR Foundation signifies a commitment to improve Alzheimer's disease diagnostics, potentially benefitting patients, families, and healthcare systems impacted by the disease.
The investment complements a prior $7.025 million boost from the Alzheimer's Drug Discovery Foundation, furthering efforts in developing mass spectrometry solutions for Alzheimer's testing globally.
Collection
[
|
...
]